» Articles » PMID: 31456031

Granulovacuolar Degeneration Bodies Are Neuron-selective Lysosomal Structures Induced by Intracellular Tau Pathology

Abstract

Granulovacuolar degeneration bodies (GVBs) are membrane-bound vacuolar structures harboring a dense core that accumulate in the brains of patients with neurodegenerative disorders, including Alzheimer's disease and other tauopathies. Insight into the origin of GVBs and their connection to tau pathology has been limited by the lack of suitable experimental models for GVB formation. Here, we used confocal, automated, super-resolution and electron microscopy to demonstrate that the seeding of tau pathology triggers the formation of GVBs in different mouse models in vivo and in primary mouse neurons in vitro. Seeding-induced intracellular tau aggregation, but not seed exposure alone, causes GVB formation in cultured neurons, but not in astrocytes. The extent of tau pathology strongly correlates with the GVB load. Tau-induced GVBs are immunoreactive for the established GVB markers CK1δ, CK1ɛ, CHMP2B, pPERK, peIF2α and pIRE1α and contain a LAMP1- and LIMP2-positive single membrane that surrounds the dense core and vacuole. The proteolysis reporter DQ-BSA is detected in the majority of GVBs, demonstrating that GVBs contain degraded endocytic cargo. GFP-tagged CK1δ accumulates in the GVB core, whereas GFP-tagged tau or GFP alone does not, indicating selective targeting of cytosolic proteins to GVBs. Taken together, we established the first in vitro model for GVB formation by seeding tau pathology in primary neurons. The tau-induced GVBs have the marker signature and morphological characteristics of GVBs in the human brain. We show that GVBs are lysosomal structures distinguished by the accumulation of a characteristic subset of proteins in a dense core.

Citing Articles

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.

Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.

PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.


Neuroinflammation in Age-Related Neurodegenerative Diseases: Role of Mitochondrial Oxidative Stress.

Abadin X, de Dios C, Zubillaga M, Ivars E, Puigros M, Mari M Antioxidants (Basel). 2025; 13(12.

PMID: 39765769 PMC: 11672511. DOI: 10.3390/antiox13121440.


Increased expression of the proapoptotic presenilin associated protein is involved in neuronal tangle formation in human brain.

Yang C, Sun Z, Jiang J, Cai X, Wang Y, Wang H Sci Rep. 2024; 14(1):25274.

PMID: 39455681 PMC: 11512019. DOI: 10.1038/s41598-024-77026-0.


Hypothesis-based investigation of known AD risk variants reveals the genetic underpinnings of neuropathological lesions observed in Alzheimer's-type dementia.

Laureyssen C, Kucukali F, Van Dongen J, Gawor K, Tome S, Ronisz A Acta Neuropathol. 2024; 148(1):55.

PMID: 39424714 PMC: 11489263. DOI: 10.1007/s00401-024-02815-w.


Regulated cell death in neurodegeneration: pathways and therapeutic horizons.

Thal D, De Strooper B Acta Neuropathol. 2024; 148(1):47.

PMID: 39317858 DOI: 10.1007/s00401-024-02808-9.


References
1.
Dickson D, Ksiezak-Reding H, Davies P, Yen S . A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration. Acta Neuropathol. 1987; 73(3):254-8. DOI: 10.1007/BF00686619. View

2.
Eidelberg D, Sotrel A, Joachim C, Selkoe D, Forman A, Pendlebury W . Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. Brain. 1987; 110 ( Pt 4):993-1013. DOI: 10.1093/brain/110.4.993. View

3.
Ikegami K, Kimura T, Katsuragi S, Ono T, Yamamoto H, Miyamoto E . Immunohistochemical examination of phosphorylated tau in granulovacuolar degeneration granules. Psychiatry Clin Neurosci. 1996; 50(3):137-40. DOI: 10.1111/j.1440-1819.1996.tb01678.x. View

4.
Kohler C . Granulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology. Acta Neuropathol. 2016; 132(3):339-59. DOI: 10.1007/s00401-016-1562-0. View

5.
Hoozemans J, van Haastert E, Eikelenboom P, de Vos R, Rozemuller J, Scheper W . Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun. 2007; 354(3):707-11. DOI: 10.1016/j.bbrc.2007.01.043. View